Anbio Biotechnology SEC filings NNNN

Anbio Biotechnology has 43 filings in SEC EDGAR's recent list, going back to Dec 27, 2023. Its latest annual report, Form 20-F, was filed on Apr 7, 2026 for the period ended Dec 31, 2025. The most recent current report (Form 6-K) was filed on May 19, 2026. The company's fiscal year ends on December 31.

Anbio Biotechnology SEC filings
Form Description Filed Period
EFFECT Filing Feb 18, 2025 —
CERT Filing Feb 18, 2025 —
CORRESP Letter to the SEC Feb 14, 2025 —
CORRESP Letter to the SEC Feb 14, 2025 —
8-A12B For registration of certain classes Feb 14, 2025 —
DRSLTR Filing Dec 11, 2024 —
DRS/A Filing Dec 11, 2024 —
UPLOAD Letter from the SEC Dec 4, 2024 —
DRS/A Filing Nov 18, 2024 —
DRSLTR Filing Jul 1, 2024 —
DRS/A Filing Jul 1, 2024 —
UPLOAD Letter from the SEC Jun 21, 2024 —
DRS/A Filing Jun 10, 2024 —
DRSLTR Filing Jun 7, 2024 —
UPLOAD Letter from the SEC Mar 22, 2024 —
DRS/A Filing Mar 11, 2024 —
DRSLTR Filing Mar 8, 2024 —
UPLOAD Letter from the SEC Jan 23, 2024 —
DRS Filing Dec 27, 2023 —

Showing 19 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.

Company profile

Industry
In Vitro & In Vivo Diagnostic Substances (SIC 2835)
Listed as
NNNN (Nasdaq)
Fiscal year ends
December 31
Incorporated in
Cayman Islands
Headquarters
Frankfurt Am Main, Germany
SEC filer status
Non-accelerated filer, Emerging growth company
SEC CIK
1982708

Other In Vitro & In Vivo Diagnostic Substances companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.